{
    "nctId": "NCT03983577",
    "briefTitle": "Efficacy of Point Of Service Testing in MBC",
    "officialTitle": "Efficacy of Point Of Service Testing in Metastatic Breast Cancer",
    "overallStatus": "RECRUITING",
    "conditions": "Metastatic Cancer, Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "NA",
    "allocation": "NA",
    "primaryPurpose": "HEALTH_SERVICES_RESEARCH",
    "enrollmentCount": 100,
    "primaryOutcomeMeasure": "Proportion of patients/participants that undergo hereditary cancer genetic testing after the telehealth intervention.",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Ability of participant OR Legally Authorized Representative (LAR) to understand this study, and participant or LAR willingness to sign a written informed consent.\n* Able to speak and read in the English language.\n* Have a diagnosis of human epidermal growth factor receptor 2 (HER2) negative metastatic breast cancer.\n* Participants must be enrolled in the parent registry study.\n\nExclusion Criteria:\n\n* Genetic testing for a breast cancer gene (BRCA) BRCA1 and BRCA2 mutation completed after 2013 or any BRCA 1 and BRCA2 testing with large rearrangement testing. Prior genetic counseling is allowed.\n* Psychiatric illness/social situations that would limit compliance with study requirements.",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}